TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

Five years of continuous Briumvi kept MS relapse rates and disability progression low, according to analyses from a trial's ...

TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted in an ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Since Sunday, Tropical Storm Enteng (international name: Yagi) has brought rains and caused heavy flooding in Metro Manila and its neighboring cities, with Signal No. 2 raised in nine areas in Luzon.

Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 ...